Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Changes in a CSF antigen associated with dementia

M T Carretero1, C R Harrington, C M Wischik

  • 1Cambridge Brain Bank Laboratory, University of Cambridge Department of Psychiatry, UK.

Dementia (Basel, Switzerland)
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Continued Impact of Acute Rejection in the Last Decade of Liver Transplantation.

Gastro hep advances·2022
Same author

Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.

The journal of prevention of Alzheimer's disease·2022
Same author

Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration.

Cellular and molecular life sciences : CMLS·2014
Same author

Addictive-like behaviours to ultraviolet light among frequent indoor tanners.

Clinical and experimental dermatology·2010
Same author

Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics.

Neuroscience letters·2002
Same author

Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's disease.

Journal of chemical neuroanatomy·2001

Researchers identified a novel 85-kDa antigen in cerebrospinal fluid (CSF) that decreases in dementia patients. Its levels correlate with Alzheimer's disease progression, offering a potential biomarker.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Immunology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Identifying reliable biomarkers for dementia diagnosis and progression is crucial.
  • Paired helical filaments (PHFs) are key pathological hallmarks in AD brains.

Purpose of the Study:

  • To detect and characterize a novel antigen in cerebrospinal fluid (CSF).
  • To investigate the antigen's potential as a biomarker for dementia, including Alzheimer's disease.
  • To explore the relationship between antigen levels and disease progression in AD patients.

Main Methods:

  • Development of a monoclonal antibody (11.57) against PHF fractions.
  • Detection and quantification of an 85-kDa antigen in CSF samples (lumbar and post-mortem).

Related Experiment Videos

  • Comparison of antigen levels between dementia patients (AD and non-AD) and non-demented controls.
  • Correlation analysis between antigen levels and disease progression in AD.

    • Main Results:

    • An 85-kDa thermostable protein antigen, distinct from tau and amyloid beta, was detected in CSF.
    • Significantly decreased levels of the 85-kDa antigen were observed in patients with dementia compared to controls.
    • No significant difference in antigen levels was found between Alzheimer's disease and non-Alzheimer's dementia.
    • A significant correlation was established between the 85-kDa antigen levels and disease progression in Alzheimer's disease.

    Conclusions:

    • The 85-kDa CSF antigen is a potential biomarker for dementia.
    • Its levels decrease with dementia onset and correlate with Alzheimer's disease progression.
    • Further research is warranted to validate its diagnostic and prognostic utility in neurodegenerative diseases.